高表达与 Claudin-low 和基底样乳腺癌的不良预后相关。
High Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers.
机构信息
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
出版信息
Anticancer Res. 2021 Jan;41(1):43-54. doi: 10.21873/anticanres.14750.
BACKGROUND/AIM: SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear.
MATERIALS AND METHODS
Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockdown using targeted siRNA on cell viability and tumor-sphere formation was assessed.
RESULTS
SLC20A1 patients with ER+, claudin-low or basal-like breast cancers showed poor prognoses. SLC20A1 patients treated with radiotherapy had poor clinical outcomes. SLC20A1 knockdown suppressed the viability of MDA-MB 231 (claudin-low), MDA-MB 468 (basal-like) and MCF-7 (ER+) cells, and tumor-sphere formation by ALDH1 cells. These results suggest that SLC20A1 is involved in cancer progression and contributes to clinical outcomes in patients with ER+, claudin-low and basal-like breast cancers.
CONCLUSION
SLC20A1 is a potential prognostic marker and therapeutic target in ER+, claudin-low and basal-like breast cancers.
背景/目的：SLC20A1 已被确定为 ER+ 乳腺癌的预后标志物。然而，SLC20A1 表达在 ER+ 类型以外的乳腺癌亚型中的作用尚不清楚。
材料和方法
下载并分析基因组数据集，并使用靶向 siRNA 评估 SLC20A1 敲低对细胞活力和肿瘤球体形成的影响。
结果
SLC20A1 患者的 ER+、claudin-low 或基底样乳腺癌预后不良。接受放疗的 SLC20A1 患者临床结局不佳。SLC20A1 敲低抑制了 MDA-MB 231（claudin-low）、MDA-MB 468（基底样）和 MCF-7（ER+）细胞的活力，以及 ALDH1 细胞的肿瘤球体形成。这些结果表明，SLC20A1 参与了癌症的进展，并导致 ER+、claudin-low 和基底样乳腺癌患者的临床结局不良。
结论
SLC20A1 是 ER+、claudin-low 和基底样乳腺癌的潜在预后标志物和治疗靶点。
Zotero 插件